Novo Nordisk AS's long and steady financial run on self-generated diabetes and obesity products is flagging – and the Danish group has acknowledged that it needs to revitalize its other product lines to generate fresh revenue growth – so reports it is interested in California-based Global Blood Therapeutics Inc. have not surprised observers.
Reuters and Bloomberg, quoting unnamed sources, reported the South San Francisco-based sickle cell drug developer has been approached by Novo...








